The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.
Luis Costa
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Karim Fizazi
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen
Fred Saad
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Research Funding - Amgen; Novartis
Janet Elizabeth Brown
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis
Honoraria - Amgen; Novartis
Research Funding - Novartis
Roger Von Moos
Consultant or Advisory Role - Amgen; Novartis; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Expert Testimony - Roche (U); Sanofi (U)
Stephane Oudard
Consultant or Advisory Role - Pfizer; Sanofi
Honoraria - Bayer; Keocyt; Novartis; Roche
Cora N. Sternberg
Honoraria - Amgen; Novartis
Vinod Ganju
No relevant relationships to disclose
Kurt Miller
Consultant or Advisory Role - Novartis
Other Remuneration - Amgen
Huei Wang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Tapan Maniar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen